Seagen Inc. disappointed most observers by not talking about the potential buyout of the company by Merck & Co., Inc. during its 28 July earnings report, keeping quiet as Merck did itself in its earnings release the same day. But the Seattle-based company did highlight fundamentals that will be a factor in a possible acquisition, including strong sales growth for its key products and an update on another closely watched situation, its legal dispute with Daiichi Sankyo Co., Ltd.
The company reported total revenue of $498m and product sales of $431.7m for the second quarter, a 24% increase over the comparable period in 2024. Adcetris (brentuximab vedotin) and Padcev (enfortumab vedotin-ejfv) saw respective sales increases of 11%, to $201.9m, and 50%, to $123.6m